Epigenomics licenses microarray technology from Affymetrix

New York, June 27 - Epigenomics AG said it has licensed non-exclusive access to Affymetrix Inc.'s microarray technology to develop and market microarray-based in-vitro diagnostic tests for oncology and other indications.

Epigenomics said the agreement complements its previously announced strategic alliance with Qiagen NV for sample preparation.

Together, with the Affymetrix arrays and DNA analysis instrumentation, Epigenomics said it can now provide a complete platform for its pathology tests based on its proprietary DNA methylation methods.

The first products will be pathology tests for prostate and breast cancer, the Berlin-based molecular diagnostics company added.

Specifically, Epigenomics is planning to transfer its Molecular Classification Test for prostate cancer onto the Affymetrix platform to use it in the pivotal clinical trial for FDA approval of the assay, which is scheduled to start next year.

Affymetrix is a Santa Clara, Calif., maker of microarrays for molecular biology research.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.